Canada: Gowling WLG Advises Aegerion Pharmaceuticals On QLT Merger To Form Novelion Therapeutics
Last Updated: December 19 2016

Gowling WLG acted as Canadian counsel to Aegerion Pharmaceuticals, Inc. (NASDAQ listed), which merged with QLT Inc. (NASDAQ and TSX listed) to form Novelion Therapeutics Inc.

On November 29, 2016, Aegerion Pharmaceuticals, Inc. completed its merger with QLT Inc. in which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the merger, QLT changed its name to Novelion Therapeutics Inc. Novelion is listed on NASDAQ and the Toronto Stock Exchange.

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases.

Gowling WLG acted as Canadian counsel to Aegerion with a team led by Henry Harris, which included Filomena Frisina, Paul Carenza, Ian Macdonald and Mariam Al-Shikarchy.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Belinda Bain, Olivia Lifman
By Jason Coates, Christopher Stiles, Joanne Tibbott
By John Coldham
By Ian Mondrow
By Daniel Wood, Clark Sargent, Cathy Moore
By Helen Davenport, Jane Bates
By Paul M. Murphy
By John Coldham
By James Sidwell, Susannah Fink, Christopher Richards
By Connie Cliff, Jane Fielding, Siobhan Bishop
Font Size: